🇺🇸 FDA
Pipeline program

RLY-8161

RLY-8161-101

Phase 1 small_molecule active

Quick answer

RLY-8161 for NRAS Mutation is a Phase 1 program (small_molecule) at Relay Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Relay Therapeutics
Indication
NRAS Mutation
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials